Innovent Biologics, a company based in China, focuses on global markets.

1 report, 1 independent Updated Jul 24

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Innovent Biologics

Keep exploring

Part of

China's biotech sector is driving global deal flow, while US Congress proposes required Treasury review of investments. All 2 developments

The entities involved

Innovent Biologics
Chinese Biopharmaceutical Company

Nothing else this week.

Related events

FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.Jun 8

Coverage

Newest first; wire copies grouped

Jul 24dailypolitical.comInnovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update